Amarillo Biosciences Inc (AMAR) Insider Stephen T. Chen Acquires 533,334 Shares

Amarillo Biosciences Inc (OTCMKTS:AMAR) insider Stephen T. Chen bought 533,334 shares of Amarillo Biosciences stock in a transaction dated Thursday, November 1st. The stock was purchased at an average price of $0.21 per share, with a total value of $112,000.14. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

AMAR stock opened at $0.59 on Thursday. Amarillo Biosciences Inc has a one year low of $0.15 and a one year high of $0.61.

Amarillo Biosciences (OTCMKTS:AMAR) last released its earnings results on Monday, August 13th. The company reported ($0.01) EPS for the quarter.

WARNING: “Amarillo Biosciences Inc (AMAR) Insider Stephen T. Chen Acquires 533,334 Shares” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2018/11/08/amarillo-biosciences-inc-amar-insider-stephen-t-chen-acquires-533334-shares.html.

About Amarillo Biosciences

Amarillo Biosciences, Inc engages in the development of biologics for the treatment of human and animal diseases. The company owns or licenses five issued patents related to the low-dose oral delivery of interferon; and owns one issued patent on its dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha.

Featured Article: Determine Your Level of Risk Tolerance

Insider Buying and Selling by Quarter for Amarillo Biosciences (OTCMKTS:AMAR)

Receive News & Ratings for Amarillo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply